Biotech Lock Up Expiration Hell Portfolio: Wave II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	10/15/2004 12:58:43 PM
	Read Replies (1) of 107

>>11:41AM Cotherix IPO opens at $6.01, after pricing poorly (CTRX) 6.04 +0.04: CoTherix prices its IPO at $6, after having lowered the expected range from $8-$10 and $12-$14. The co is a development stage biotech co focused on therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, its lead product candidate, is an inhaled formulation of iloprost which is similar to prostacyclins, which are naturally-occurring molecules that cause blood vessels to dilate. Ventavis is currently marketed in various European countries and Australia by Schering AG...Biotech IPOs have made a comeback recently, hopefully this does not restart the trend in the other direction. This is a 5 mln share deal led by CIBC and Piper.<< Courtesy of Briefing.com Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next